ResearcherShanxi Medical UniversityActive in the last 2 years

Qing Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3171-4896; OpenAlex author ID A5100404076. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

The prognostic significance of twist in pancreatic cancer and its role in cancer promotion through the regulation of the immune microenvironment and EMT mechan… Co-author DOI 10.1007/s12672-024-01478-z ↗
The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB … Co-author DOI 10.1016/j.clim.2022.109217 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yinquan Wang · 1 shared paper, 2024 · strength 0.31
- Paper The prognostic significance of twist in pancreatic cancer and its role in cancer promotion through the regulation of th… DOI 10.1007/s12672-024-01478-z ↗
Senlin Li · 1 shared paper, 2023 · strength 0.18
- Paper The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic c… DOI 10.1016/j.clim.2022.109217 ↗
Ferdinando Nicoletti · 1 shared paper, 2023 · strength 0.18
- Paper The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic c… DOI 10.1016/j.clim.2022.109217 ↗
Cheng Tian · 1 shared paper, 2023 · strength 0.18
- Paper The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic c… DOI 10.1016/j.clim.2022.109217 ↗
Ming Xiang · 1 shared paper, 2023 · strength 0.18
- Paper The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic c… DOI 10.1016/j.clim.2022.109217 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.